Abbott Laboratories (ABT) $104.14
Abbott Laboratories finds itself at a critical juncture, trading near its 52-week low amidst a broad market pullback, presenting a potential value play for discerning investors.
52-wk High $139.06
📌 Investment Snapshot
- 💰 Trading at $104.14, ABT sits just 0.5% above its 52-week low, with a TTM P/E of 27.99x.
- 📈 Latest reported revenue hit $11.46B with EPS of $1.01 in Q4 2025.
- 🔑 The stock is deeply oversold (RSI 22.4), suggesting a potential bounce from current levels.
- 🎯 Analysts maintain a Buy consensus with a $132.64 mean target, implying 27.36% upside.
Despite being technically oversold (RSI 22.4) and offering 27.36% upside to consensus, the weak technical confluence score (30/100) and recent insider selling warrant caution, suggesting a WAIT for clearer bullish signals.
| 📍 Entry Zone | $103.96 or below | 🛑 Stop-Loss | $100.00 |
| 📋 Adjust If | A confirmed break above the $108.77 Bollinger Band mid-line or positive insider buying emerges. | ||
The Investment Case — Why Now?
Abbott Laboratories has seen its share price tumble over 25% from its 52-week high, landing squarely at the bottom of its annual range. This significant pullback, coupled with an RSI of 22.4, indicates the stock is deeply oversold by traditional metrics. While the broader market has shown some weakness (S&P 500 down 1.96% in 1W), ABT’s decline has been more pronounced, potentially creating a compelling entry point for long-term investors seeking value in a high-quality medical device play.
However, the lack of a strong positive catalyst and persistent insider selling throughout March 2026, including a significant sale by Officer ORVILLE JACOB A, raise red flags. This internal sentiment, combined with a weak technical confluence score of 30/100, suggests that while the stock is cheap, the bottom may not be definitively in. You must weigh the attractive valuation against these cautionary signals.
🤔 Given the deep discount and oversold conditions, are you willing to overlook the insider selling and weak technicals for a potential long-term rebound?
🏢 Company Overview
| Detail | Value |
|---|---|
| Company | Abbott Laboratories |
| Ticker / Exchange | ABT / NYSE |
| Sector / Industry | Healthcare / Medical Devices |
| CEO | Robert B. Ford |
| Founded / HQ | 1888 / Abbott Park, IL |
📈 Price Action & Technicals
Dead Cross
Outside VA
A buy-side liquidity sweep occurred at $108.34 on March 13, 2026, indicating some institutional interest on the dip.
Abbott’s price action paints a bearish picture, with the stock trading significantly below both its 50-day ($111.04) and 200-day ($124.14) Simple Moving Averages. This sustained downtrend is further confirmed by the ADX reading of 39.2, indicating a strong bearish trend where the -DI (30.5) clearly dominates the +DI (10.2).
The RSI of 22.4 unequivocally places ABT in deeply oversold territory, a level often preceding a bounce or consolidation. However, the MACD crossover to the downside (MACD -2.37 below signal -1.94) suggests that while oversold, immediate upward momentum remains elusive. This divergence creates a complex technical landscape for traders.
From a volume perspective, the price sits just below the Anchored VWAP ($104.26) from March 24, 2026, and critically, outside the Value Area ($105.11-$132.14) with the Point of Control (POC) far higher at $124.71. This implies that the current price is in an area of low historical trading interest, making it vulnerable to further downside or requiring significant buying pressure to re-enter the value zone.
The stock is currently hugging the lower Bollinger Band ($102.14), indicating extreme price compression and potential for a volatility expansion. While buy-side liquidity sweeps were observed at $108.34 and $111.18 earlier in March, the current volume ratio is a mere 0.02x of its 20-day average, signaling a severe lack of conviction from either bulls or bears at these levels. The Technical Confluence Score of 30/100 reinforces this weak technical outlook.
Historically, when ABT has reached such oversold RSI levels near its 52-week low, a bounce has often followed, but the absence of significant volume and strong bearish trend indicators (ADX, MACD) suggest this bounce might be delayed or muted without a fundamental catalyst. The unfilled bearish FVGs at higher levels ($110.05-$120.33, $114.43-$115.49) represent potential resistance zones should a recovery materialize.
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| ABT | Abbott Laboratories | 27.99x |
| MDT | Medtronic plc | 23.5x |
| JNJ | Johnson & Johnson | 18.2x |
| DHR | Danaher Corporation | 32.1x |
| S&P 500 | Index Average | 21.0x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q4 2025 | $11.46B | $1.01 | |
| Q3 2025 | $11.37B | $0.94 | |
| Q2 2025 | $11.14B | $1.01 | |
| Q1 2025 | $10.36B | $0.76 |
Abbott demonstrates robust financial health, generating $2.6B in Free Cash Flow in the latest quarter. The company also returned $0.3B to shareholders through buybacks, alongside its 2.41% dividend yield, underscoring its commitment to shareholder value.
🚀 Growth Drivers — What Moves the Stock
- Diverse Product Portfolio 🟡 Priced In — Abbott’s broad portfolio across established pharmaceuticals, diagnostics, nutrition, and medical devices provides resilience and multiple avenues for growth, insulating it from single-market volatility.
- Aging Global Population 🟢 Upside Surprise — The increasing global elderly population drives demand for Abbott’s medical devices and diagnostics, particularly in cardiovascular, diabetes, and vision care, offering a long-term demographic tailwind.
- Continuous Innovation 🟢 Upside Surprise — Ongoing R&D investments in areas like continuous glucose monitoring (FreeStyle Libre) and structural heart devices position Abbott at the forefront of medical technology, driving future revenue streams.
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Vanguard Group Inc | 175,556 |
| Blackrock Inc. | 146,908 |
| State Street Corporation | 79,853 |
| Capital International Investors | 63,229 |
| Capital Research Global Investors | 39,169 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| ORVILLE JACOB A | Officer | Mar 23, 2026 | Sale | 13,255 |
| EARNHARDT LISA D | Officer | Feb 24, 2026 | Sale | 27,056 |
| SALVADORI DANIEL GESUA SIVE | Officer | Mar 2, 2026 | Sale | 885 |
| MCCOY JOHN A. JR | Officer | Mar 2, 2026 | Sale | 585 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 0.0% | 2.4 |
⚠ Key Risk Factors
~$500M revenue impact
~2% margin erosion
~$1B recall cost
Negative investor perception
🤔 With the stock trading at a discount, how much weight do you place on the current macroeconomic uncertainty and the recent wave of insider selling?
🎯 Guidance & Wall Street View
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $158.0 | $132.64 | $113.0 | 25 | Buy |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| Citigroup | Buy | Mar 2026 | Maintains | |
| Barclays | Overweight | Feb 2026 | Maintains | |
| Freedom Broker | Buy | Jan 2026 | Upgraded | |
| Bernstein | Outperform | Jan 2026 | Maintains | |
| RBC Capital | Outperform | Jan 2026 | Maintains |
Despite the recent price weakness, Wall Street analysts remain overwhelmingly bullish on ABT, with 25 firms maintaining a ‘Buy’ consensus and projecting a 27.36% upside to the mean target of $132.64. This strong institutional conviction provides a fundamental floor for the stock.
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- Deeply oversold RSI (22.4) and trading at 52-week lows could trigger a significant technical rebound, especially with a 27.36% upside to consensus target.
- Abbott’s robust FCF ($2.6B) and diverse, essential product portfolio provide a strong fundamental base, attracting long-term value investors.
📊 Base Case
Our base case suggests Abbott will continue to navigate market challenges, maintaining its strong market position in key medical device and diagnostics segments. The current oversold condition may lead to a modest recovery, but without a clear catalyst or improved technicals, significant upside is capped in the near term. Fair value is estimated closer to the analyst low target, reflecting current headwinds.
🐻 Bear Case
- Persistent insider selling and a weak technical confluence score (30/100) indicate further downside potential, potentially breaking the 52-week low.
- Macroeconomic pressures and intense competition could further compress margins and slow revenue growth, leading to downward revisions in analyst estimates.
🎯 Investor Action Plan — By Profile
Swing traders should AVOID ABT for now. While oversold, the strong bearish trend (ADX 39.2) and lack of buying volume mean a reversal is not imminent. Wait for a confirmed break above the $108.77 Bollinger Band mid-line with increased volume.
Position investors should WAIT for a clearer entry. The current price is attractive, but insider selling and a weak technical score suggest the bottom may not be in. Consider scaling in if the stock holds the $103.96 support and shows signs of accumulation.
Long-term investors interested in ABT’s quality should WAIT for improved technicals or a positive fundamental catalyst. While the dividend yield (2.41%) is appealing, the current price action and insider sentiment warrant patience before initiating a full position.
❓ Investor FAQ — People Also Ask
Q: Why is Abbott Laboratories stock currently trading near its 52-week low?
ABT has experienced a significant 25.1% decline from its 52-week high, driven by broader market volatility (VIX at 27.92) and potentially specific sector headwinds. The stock’s RSI of 22.4 indicates it is deeply oversold, reflecting this recent downward pressure.
Q: What do the technical indicators suggest about ABT’s immediate future?
Technically, ABT is oversold (RSI 22.4) and trading below its key moving averages, indicating a strong bearish trend (ADX 39.2). The weak Technical Confluence Score of 30/100 suggests a lack of alignment among bullish signals, implying that while a bounce is possible, a sustained reversal needs stronger confirmation.
Q: Should I be concerned about the recent insider transactions?
Yes, the consistent insider selling by multiple officers throughout March 2026, including a significant sale by ORVILLE JACOB A, is a notable concern. While not always indicative of future performance, it often signals a lack of immediate upside conviction from those with the most intimate knowledge of the company.
📋 Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. Always conduct your own due diligence and consult with a professional financial advisor before making any investment decisions. The views expressed are solely those of the analyst and do not represent the opinions of Goldman Sachs or any affiliated entities. Investment in securities involves risks, including the potential loss of principal.
All active positions and their real-time performance are tracked on our Investment Log.
#ABT #AbbottLaboratories #MedicalDevices #HealthcareStocks #StockAnalysis #NYSE #Investing #Veqtio